Stock Events

Stock Events

Supernus Pharmaceuticals 

$44.07
13
+$0.10+0.23% 18:35 Today

Statistics

Day High
44.11
Day Low
43.56
52W High
59.68
52W Low
42.45
Volume
192,115
Avg. Volume
841,890
Mkt Cap
2.56B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.3
0.53
0.77
1.01
Expected EPS
0.615
Actual EPS
N/A

Financials

-5.36%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
718.95MRevenue
-38.55MNet Income

Analyst Ratings

67.00Average Price Target
The highest estimate is 67.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SUPN. It's not an investment recommendation.
Pfizer
7
PFE
Apple
6
AAPL
Microsoft
6
MSFT
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly with Supernus in the CNS and neurology markets.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.87B
Jazz Pharmaceuticals focuses on developing and commercializing innovative pharmaceuticals, including for neurological conditions, directly competing with Supernus.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals specializes in the development and commercialization of medicines to treat central nervous system disorders, competing in similar markets as Supernus.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc is involved in the development and commercialization of pharmaceuticals for CNS diseases, including schizophrenia and depression, areas where Supernus also operates.
Neurocrine Biosciences
NBIX
Mkt Cap15.66B
Neurocrine Biosciences develops and markets pharmaceuticals for neurological and endocrine-related diseases and disorders, competing in the same therapeutic areas as Supernus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen, a biotechnology giant, has a diverse portfolio that includes treatments for neurological disorders, indirectly competing with Supernus in some areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, and its portfolio includes treatments for multiple sclerosis and spinal muscular atrophy, competing with Supernus in the neurology space.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a broad portfolio that includes CNS treatments, such as Parkinson's and Alzheimer's disease medications, making it a competitor in the neurology market.

About

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Show more...
CEO
Jack A. Khattar
Employees
778
Country
United States
ISIN
US8684591089
WKN
000A1JX3U

Listings

STU
DE
S49.STU
F
DE
S49.F
LSE
GB
0LB2.LSE
BOATS
BOATS
SUPN.BOATS

0 Comments

Share your thoughts

FAQ

What is Supernus Pharmaceuticals stock price today?▼
The current price of SUPN is $44.07 USD — it has increased by +0.23% in the past 24 hours. Watch Supernus Pharmaceuticals stock price performance more closely on the chart.
What is Supernus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Supernus Pharmaceuticals stocks are traded under the ticker SUPN.
Is Supernus Pharmaceuticals stock price growing?▼
SUPN stock has risen by +0.56% compared to the previous week, the month change is a +1.68% rise, over the last year Supernus Pharmaceuticals has showed a -3.2% decrease.
What is Supernus Pharmaceuticals market cap?▼
Today Supernus Pharmaceuticals has the market capitalization of 2.56B
When is the next Supernus Pharmaceuticals earnings date?▼
Supernus Pharmaceuticals is going to release the next earnings report on November 10, 2026.
What were Supernus Pharmaceuticals earnings last quarter?▼
SUPN earnings for the last quarter are 0.53 USD per share, whereas the estimation was 0.42 USD resulting in a +24.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Supernus Pharmaceuticals revenue for the last year?▼
Supernus Pharmaceuticals revenue for the last year amounts to 718.95M USD.
What is Supernus Pharmaceuticals net income for the last year?▼
SUPN net income for the last year is -38.55M USD.
How many employees does Supernus Pharmaceuticals have?▼
As of September 04, 2026, the company has 778 employees.
In which sector is Supernus Pharmaceuticals located?▼
Supernus Pharmaceuticals operates in the Health & Wellness sector.
When did Supernus Pharmaceuticals complete a stock split?▼
Supernus Pharmaceuticals has not had any recent stock splits.
Where is Supernus Pharmaceuticals headquartered?▼
Supernus Pharmaceuticals is headquartered in ROCKVILLE, United States.